Trans-2-nonadecyl-4-(hydroxymethyl)-1,3-dioxolane (TNHD) purified from freshwater clams markedly alleviates dimethylnitrosamine-induced hepatic fibrosis.

Publisher: Food and Drug Administration, Taiwan Country of Publication: China (Republic : 1949- ) NLM ID: 101630927 Publication Model: Print Cited Medium: Internet ISSN: 2224-6614 (Electronic) NLM ISO Abbreviation: J Food Drug Anal Subsets: MEDLINE

Publication: [Taipei, Taiwan] : Food and Drug Administration, Taiwan
Original Publication: [Taipei City, Taiwan, R.O.C.] : Elsevier, 2013-

Dimethylnitrosamine*/toxicity ; Bivalvia*/genetics ; Dioxolanes*; Animals ; Liver Cirrhosis/chemically induced ; Liver Cirrhosis/drug therapy ; Liver Cirrhosis/genetics ; Inflammation

Liver fibrosis occurs due to injury or inflammation, which results in the excessive production of collagen and the formation of fibrotic scar tissue that impairs liver function. Despite the limited treatment options available, freshwater clams may hold promise in the treatment of liver fibrosis. In this study, we demonstrated the effects of ethanol extract of freshwater clam (FCE), ethyl acetate extract of FCE (EA-FCE), and trans-2-nonadecyl-4-(hydroxymethyl)-1,3-dioxolane (TNHD) on liver fibrosis induced by dimethylnitrosamine (DMN). Administration of FCE and TNHD alleviated liver injury, including tissue damage, necrosis, inflammation scores, fibrosis scores, serum enzymes, and triglyceride levels. Furthermore, we analyzed the expression of fibrosis-related proteins, such as α-smooth muscle actin (α-SMA) and transforming growth factor (TGF-β), as well as the hydroxyproline content, which decreased after treatment with FCE and TNHD. Animal experiments revealed that FCE and TNHD can reduce liver fibrosis by inhibiting cytokines that activate stellate cells and decreasing extracellular matrix (ECM) secretion. Cell experiments have shown that TNHD inhibits the MAPK/Smad signaling pathway and TGF-β1 activation, resulting in a reduction in the expression of fibrosis-related proteins. Therefore, freshwater clam extracts, particularly TNHD, may have potential therapeutic and preventive effects for the amelioration of liver fibrosis.

Nat Rev Gastroenterol Hepatol. 2021 Mar;18(3):151-166. (PMID: 33128017)
Mol Med Rep. 2013 Dec;8(6):1623-9. (PMID: 24100678)
Am J Chin Med. 2010;38(5):881-94. (PMID: 20821820)
J Gastroenterol Hepatol. 2007 Jun;22 Suppl 1:S73-8. (PMID: 17567473)
J Gastroenterol Hepatol. 2006 Oct;21 Suppl 3:S84-7. (PMID: 16958681)
Anal Biochem. 1981 Mar 15;112(1):70-5. (PMID: 7258630)
Biochim Biophys Acta. 1996 Feb 8;1292(2):215-22. (PMID: 8597566)
J Ethnopharmacol. 2021 Nov 15;280:114414. (PMID: 34314804)
J Natl Cancer Inst. 1978 Nov;61(5):1285-9. (PMID: 30846)
Toxicol Appl Pharmacol. 1992 Sep;116(1):110-6. (PMID: 1382324)
Food Chem Toxicol. 2006 Aug;44(8):1261-72. (PMID: 16545898)
Food Funct. 2013 Feb 26;4(3):470-5. (PMID: 23291610)
Int J Cancer. 2012 Jul 1;131(1):193-200. (PMID: 21805476)
Am Fam Physician. 1999 Apr 15;59(8):2223-30. (PMID: 10221307)
J Med Food. 2015 Mar;18(3):290-8. (PMID: 25133972)
Adv Anat Embryol Cell Biol. 2001;161:III-XIII, 1-151. (PMID: 11729749)
J Biol Chem. 2005 Mar 18;280(11):10055-64. (PMID: 15647278)
Front Biosci. 2002 Apr 01;7:d793-807. (PMID: 11897555)
Am J Clin Pathol. 1957 Jul;28(1):56-63. (PMID: 13458125)
Biomed Res Int. 2018 Dec 2;2018:1682743. (PMID: 30627538)
J Hepatol. 2003;38 Suppl 1:S38-53. (PMID: 12591185)
J Histochem Cytochem. 2000 Oct;48(10):1331-9. (PMID: 10990487)
Cell Physiol Biochem. 2018;50(5):1711-1725. (PMID: 30384360)
Gastroenterology. 2008 May;134(6):1655-69. (PMID: 18471545)
Drug Chem Toxicol. 2016;39(1):111-8. (PMID: 26045230)
Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1261-8. (PMID: 20447919)
Curr Med Chem. 2012;19(28):4850-60. (PMID: 22709007)
Evid Based Complement Alternat Med. 2021 Nov 12;2021:6065168. (PMID: 34804181)
J Food Biochem. 2020 Mar;44(3):e13146. (PMID: 31944325)
Biochem Soc Trans. 2007 Aug;35(Pt 4):661-4. (PMID: 17635115)
Toxicology. 2001 Jan 2;156(2-3):129-38. (PMID: 11164615)
Biochem Pharmacol. 2000 Feb 15;59(4):357-67. (PMID: 10644043)
Biomaterials. 2011 Feb;32(5):1438-45. (PMID: 21074845)
Digestion. 1995;56(5):335-46. (PMID: 8549875)
Arch Intern Med. 2000 Nov 27;160(21):3227-30. (PMID: 11088082)
Eur J Pharmacol. 2016 Jul 15;783:92-102. (PMID: 27151496)
Inhal Toxicol. 2020 Sep - Oct;32(11-12):419-430. (PMID: 33148071)
Diabetes Metab Res Rev. 2012 Feb;28(2):109-22. (PMID: 21898753)
Int J Biol Macromol. 2020 Jan 1;142:1-10. (PMID: 31805321)
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2650-2666. (PMID: 31401364)
FASEB J. 1992 Jan 6;6(2):724-30. (PMID: 1537462)
J Dig Dis. 2009 Feb;10(1):7-14. (PMID: 19236541)

Y57RBG19JL (formal glycol)
M43H21IO8R (Dimethylnitrosamine)
0 (Dioxolanes)

Date Created: 20240325 Date Completed: 20240326 Latest Revision: 20240327

20240327

PMC10962651

10.38212/2224-6614.3491

38526593